Log in to your Inderes Free account to see all free content on this page.
Pharma Equity Group
0.299 DKK -0.33%HC Andersen Capital receives payment from Pharma Equity Group for a DigitalIR/Corporate Visibility agreement. See disclaimer.
11 investors are following this company
Pharma Equity Group develops new medicines for the local treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The company uses repositioning of existing drugs and brings drug candidates to a clinical phase III stage, after which it is handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the company.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
PEG
Daily low / high price
0.276 / 0.325
DKK
Market cap
305.87M DKK
Turnover
361.85K DKK
Volume
1.2M
Latest research
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
Claus Thestrup
CEO, Sweden
Financial calendar
Interim report
16.05.2024
Interim report
16.08.2024
Interim report
15.11.2024
ShowingAll content types
The Board of Director's decision to issue convertible loans
Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051.
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio